To,
The Shareholders,
Your Directors have pleasure in presenting the 30th
(Thirtieth) Annual Report together with the Audited Financial Statements of the Lincoln
Pharmaceuticals Limited ("the Company" or "LPL') for the year ended
March 31, 2024.
In compliance with the applicable provisions of Companies Act, 2013,
(including any statutory modification(s) or re-enactment(s) thereof, for time being in
force) ("the Act") and the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing
Regulations"), this report covers the financial results and other developments during
the financial year ended March 31, 2024, in respect of the Company.
1. FINANCIAL AND OPERATIONAL HIGHLIGHTS:
The Standalone & Consolidated financial performance of the company
for the financial year ended March 31, 2024 are summarised below:-
(' In Lakhs)
Particulars |
Standalone
Basis |
Consolidated
Basis |
For the
Year Ended March 31, 2024 |
For the
Year Ended March 31, 2023 |
For the
Year Ended March 31, 2024 |
For the
Year Ended March 31, 2023 |
Revenue from
Operations |
58,05496 |
51,030.88 |
58,05496 |
51,030.88 |
Other income |
3,442.25 |
2248.35 |
3,442.25 |
2,247.29 |
Total Income |
61,497.21 |
53,279.23 |
61,497.21 |
53,278.17 |
Profit
before Depreciation, Finance Costs and Taxation |
13,432.99 |
11,165.03 |
13,433.22 |
11,167.60 |
Less:
Depreciation |
(1,062.47) |
(916.61) |
(1,062.47) |
(916.61) |
Less:
Finance Cost |
(146.26) |
(202.89) |
(146.49) |
(203.01) |
Profit
before Taxation |
12,224.26 |
10,045.53 |
12,224.26 |
10,047.98 |
Less: Tax
Expenses |
(2,893.77) |
(2,755.59) |
(2,893.77) |
(2,758.05) |
Profit after
Tax |
9,330.49 |
7,289.94 |
(9,330.49) |
7,289.93 |
Other
Comprehensive Income |
6.11 |
(29.78) |
6.11 |
(29.78) |
Total
comprehensive income for the year |
9,336.60 |
7,260.16 |
9,336.60 |
7,260.15 |
2. STATE OF COMPANY'S AFFAIRS / OPERATIONS:
The Highlights of the company's performance (standalone) for the
year ended March 31, 2024 are as under:
The Company reports 13.76% rise in the revenue from operations of '
58,054.96 Lakhs (Domestic ' 21804.01 Lakhs and Exports ' 3625095 Lakhs) as against '
51,030.88 Lakhs (Domestic ' 21,720.35 Lakhs and Exports ' 29,310.53 Lakhs) in the previous
year. EBITDA for the year was ' 13,43299 Lakhs (increase 20.31%) as against ' 11,165.03
Lakhs in the previous year. The profit after tax has increased to ' 9330.49 Lakhs on a
standalone basis as against profit after tax of ' 728994 Lakhs in previous year
representing growth rate of 2799% during the financial year ended March 31, 2024. EPS for
the year was ' 46.58 (increase 2797%) per share as compared to ' 36.40 in the previous
year. Detailed working on operation of the Company is provided in the management
discussion and analysis report as forms part of this.
3. CONSOLIDATED FINANCIAL STATEMENTS:
In accordance with the provisions of the section 133 of the Act and the
SEBI Listing Regulations read with IND AS - 110 - consolidated financial statement, the
consolidated audited financial statement for the financial year ended March 31, 2024 forms
part of this annual report.
4. CREDIT RATING:
The ratings given by CRISIL for long term bank loan facilities and
short term bank loan facilities of the Company are CRISIL A/Stable and CRISIL
A1' respectively. There was no revision in the said ratings during the year under
review.
5. DIVIDEND:
Your company has an incessant dividend payment history and considering
the financial performance of the Company, the Board of Directors on May 16, 2024 has
recommended a dividend of ' 1.80/- (Rupees One and Paise Eighty only) per equity share on
2,00,29,728 equity shares of face value of ' 10/- each (i.e. 18%) for the financial year
ended March 31, 2024 [Previous Year ' 1.50 (Rupees Rne and Paise fifty only) per equity
share (i.e. 15%)]. Dividend is subject to approval of members at the ensuing annual
general meeting ("AGM"). The said dividend is in line with the Dividend
Distribution Policy of the Company. In view of the changes made under the Income-Tax Act,
1961, by the Finance Act, 2020, dividends paid or distributed by the Company shall be
taxable in the hands of the shareholders. The Company shall, accordingly, make the payment
of Dividend after deduction of tax at source, as may be applicable.
6. DIVIDEND DISTRIBUTION POLICY:
In terms of Regulation 43A of the SEBI Listing Regulations, the Board
of the Company has adopted a Dividend Distribution Policy, which can be accessed on the
Company weblink:
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LQDR/
8.%20Dividend%20Distribution%20Policy.pdf?_t=1676643338 .
7 TRANSFER TO RESERVES:
During the year under review, your company has transferred a sum of '
50.00 Lakhs to the general reserve out of the amount available for appropriation for the
financial year ended March 31, 2024 (Previous Year transferred a sum of ' 50.00 Lakhs was
transferred to general reserve).
8. TRANSFER OF UNCLAIMED DIVIDEND TO THE INVESTOR EDUCATION AND
PROTECTION FUND (IEPF):
In accordance with the provisions of sections 124 and 125 of the Act
and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules,
2016 ("IEPF Rules"), and relevant circulars and amendments thereto, the amount
of dividends of the company which remain unpaid or unclaimed for a period consecutive
seven years from the date of transfer to the unpaid dividend account shall be transferred
by the company to the Investor Education and Protection Fund ("IEPF"),
constituted by the Central Government.
In terms of the foregoing provisions of the Act, the company will
transfer outstanding unpaid or unclaimed dividend and corresponding shares for the
financial year 2016-2017 to the IEPF authorities during the year under review.
9. TRANSFER OF SHARES TO IEPF:
Pursuant to the provisions of IEPF Rules, all equity shares in respect
of which dividend has been unpaid / unclaimed since last seven consecutive years shall be
transferred by the Company to the designated demat account of the IEPF Authority within a
period of thirty days of such shares becoming due to be transferred.
The Company has sent reminders to all such shareholders who have not
claimed their dividends. Members who have not en-cashed dividend for the FY 2016-17 or any
subsequent dividend declared by the Company, are advised to write to the Company Secretary
of the Company immediately.
Any shareholder whose dividend/shares are transferred to IEPF can claim
the shares by making an online application in Form IEPF-5 (available on www.iepf.gov.in) .
10. SHARE CAPITAL STRUCTURE:
During the year under review, there has been no change in the
authorised share capital of the Company. The authorised share capital of the Company as on
31 March, 2024 stood at ' 20,02,97,280 divided into 2,00,29,728 equity share of '
10/-each.
During the year under review, the Company has neither issued shares
with differential voting rights nor sweat equity shares.
11. DIRECTORS AND KEY MANAGERIAL PERSONNEL:
I. Retire by Rotation of Director:
In accordance with the provisions of Section 152 of the Act and the
rules framed there under, Mr. Kishor Meghji Shah, Non-Executive Director and Mr. Munjal M.
Patel, Whole Time Director ofthe Company retire by rotation at the ensuing AGM and they
being eligible offer themselves for re-appointment. The Board recommends their
reappointment.
Necessary resolutions have been proposed in notice convening ensuing
AGM for approval of shareholders.
The brief profile of the Directors appointing / reappointing has been
detailed in the Notice convening the AGM of the Company. Your Directors recommend all
appointment / rotation / re-appointment of Directors mentioned in the notice.
II. Appointment / Re-appointment of Director:
During the year under review there is no appointment/re-appointment of
Directors.
Post March 31, 2024, pursuant to recommendation of the Nomination and
Remuneration Committee, the Board had, on April 01, 2024 appointed Mr. Naresh P. Suthar
(DIN:03261937) and Ms. Seema Mehta (DIN:10540549) as Additional Directors in the category
of Independent Directors for a term of 5 yearswith effect from April 01, 2024 to March 31,
2029, subject to approval of the shareholders of the Company.
The said appointments were approved by shareholders of the Company vide
special resolution passed through postal ballot by e-voting on May 20, 2024.
III. Resignation/Cessationof Director:
- During the year under the review, Mr. Anand Arvindbhai Patel
(DIN:00103316), resigned w.e.f. May 25, 2023 as a Whole Time Director of the company due
to personal reasons.
- During the financial year, Ms. Meha Patel (DIN:07254852),
Non-Executive Independent Director of the Company has resigned from the position of Woman
Independent director of the Company w.e.f. February 16, 2024 due to personal commitments.
- During the year, Mr. Pirabhai Suthar (DIN: 00453047) ceased to be an
Independent Director of the Company upon completion of his second and final term w.e.f.
closing of business hours on March 31, 2024.
The Board expresses their appreciation to all the three directors for
the valuable guidance and services rendered by them during their tenure as a Director of
the Company.
IV. Key Managerial Personnel:
There is no change in the Key Managerial personnel of the Company
during the year under review.
Pursuant to the provisions of Section 203 of the Act, the KMPs of the
Company as on March 31, 2024, are:
1. Mr. Mahendra G. Patel, Managing Director
2. Mr. Darshit A. Shah, Chief Financial Officer
3. Ms. Trusha Shah, Company Secretary & Compliance Officer
4. DECLARATION GIVEN BY INDEPENDENT DIRECTORS:
The Company has received the necessary declarations from all the
independent directors of the Company in accordance with Section 149 (7) of the Act and
Regulation 16 (1) (b) and 25 (8) of the SEBI Listing Regulations confirming that they meet
the criteria of independence prescribed under the Act and the SEBI Listing Regulations.
All the Independent Directors have also confirmed that in terms of Rule 6(3) of the
Companies (Appointment and Qualification of Directors) Rules, 2014, they have registered
themselves with the Independent Director's database as prescribed under the Act.
Further, in terms of Rule 6(4) of the Companies (Appointment and Qualification of
Directors) Rules, 2014, out of two Independent Di rectors of the Company as on March 31,
2024, one Independent Di rector has passed the Online Proficiency Self-Assessment Test
conducted by Indian Institute of Corporate Affairs (IICA) and one Independent Directors
was exempted from appearing for Online Proficiency Self-Assessment Test as required by
IICA.
In the opinion of the board, there has been no change in the
circumstances which may affect their status as independent directors and the board is
satisfied of the integrity, expertise and experience (including proficiency in terms of
Section 150 (1) of the Act and applicable rules thereunder) to all independent directors
on the board.
The Board is of opinion that all the Independent Directors of the
Company possess required integrity, expertise and experience (including the proficiency).
5. PERFORMANCE EVALUATION OF THE BOARD AS WHOLE, COMMITTEE AND
INDIVIDUAL DIRECTORS:
Pursuant to the provisions of the Act and the SEBI Listing Regulations,
the Board has carried out an annual evaluation of its own performance and that of its
Committees as well as performance of the Directors individually. Feedback was sought by
way of a structured questionnaire covering various aspects of the board's functioning
such as adequacy of the composition of the board and its committees, board's culture,
execution and performance of specific duties, obligations and governance and the
evaluation was carried out based on responses received from the directors.
The evaluation is performed by the board, nomination and remuneration
committee and independent directors with specific focus on the performance and effective
functioning of the Board and individual directors. In line with SEBI Circular No.
SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017, the Company adopted the criteria
recommended by the SEBI. The performance evaluation of the chairman and non-independent
directors was also carried out by the independent directors. The performance of the
directors, the board as a whole and committee of the board were found to be satisfactory.
During the year under review, the performance evaluation of the Board,
Committees and Directors was conducted based on the criteria, frame work and
questionnaires approved by the Nomination and Remuneration Committee and the Board. The
details of the performance evaluation exercise conducted by the Company are set out in the
Corporate Governance Report.
6. CHANGE(S) IN THE NATURE OF BUSINESS:
There was no change in the nature of business of the Company during the
FY ended March 31, 2024.
7 POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION:
In terms of the requirements under the Act and SEBI Listing
Regulations, the Company has in place a Nomination & Remuneration Policy, inter-alia,
detailing the director's appointment, remuneration, criteria for determining
qualifications, attributes, independence of a director and other matters. The remuneration
paid to the Directors, Key Managerial Personnel and Senior Management is as per the
Nomination & Remuneration Policy of your Company. The said Nomination &
Remuneration Policy which can be accessed on the Company weblink:
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LQDR/
13.%20Nomination%20and%20Remuneration%20Policy.pdf?_t=1676711629 .
8. DIRECTORS' RESPONSIBILITY STATEMENT:
In accordance with the provisions of Section 134(5) (c) of the Actand
based on the information provided by the management, the Directors state that:
a) in the preparation of the annual accounts for the year ended March
31, 2024, the applicable accounting standards have been followed along with proper
explanation relating to material departures, if any;
b) the directors have selected such accounting policies and applied
them consistently and made judgments and estimates that are reasonable and prudent so as
to give a true and fair view of the state of affairs of the Company at the end of the
financial year on March 31, 2024 and of the profit of the Company for the year under
review;
c) the directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of the Act
for safeguarding the assets of the Company and for preventing and detecting fraud and
other irregularities;
d) the annual accounts have been prepared on a going concern basis;
e) the directors had laid down internal financial controls to be
followed by the Company and that such internal financial controls are adequate and were
operating effectively; and
f) the directors had devised proper systems to ensure compliance with
the provisions of all applicable laws and that such systems were adequate and operating
effectively.
9. NUMBER OF MEETINGS OF THE BOARD:
During the FY 2023-2024, 4 (Four) meetings of the Board of Directors of
the Company were held and the details of Board and Committee meetings held are provided in
the Report on Corporate Governance, which forms part of this report.
10. SECRETARIAL STANDARDS:
The Company has followed the applicable secretarial standards issued by
the Institute of Company Secretaries of India (ICSI).
11. INTERNAL FINANCIAL CONTROL AND ITS ADEQUACY:
The internal control framework is intended to ensure proper
safeguarding of assets, maintaining proper accounting records and providing reliable
financial information and other data. This system is accompanied by internal audit,
reviewed by the management and performed as per documented policies, guidelines and
procedures.
The Company has a well-defined organizational structure, authority
levels, internal rules and guidelines for conducting business transactions. The Company
intends to undertake additional measures as necessary in line with its intent to adhere to
procedures, guidelines and regulations as applicable in a transparent manner. The internal
audit department of the Company carries out the internal audit of the Company operations
and reports its finding to the audit committee.
In this process, the internal audit also evaluates the functioning and
quality of internal controls and provides assurance of its adequacy and effectiveness
through periodic reporting. The internal audit is carried out as per risk based internal
audit plan which is reviewed by the audit committee of the Company.
The committee periodically reviews the findings and suggestions for
improvement and is apprised of the implementation status in respect of the actionable
items.
12. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL
POSITION OF THE COMPANY:
There are no material changes and commitments affecting the financial
position of the Company which occurred between the financial year ended March 31, 2024 to
which the financial statements relates and the date of signing of this report.
13. DEPOSITS:
The Company has not accepted any deposits from the public in terms of
Section 73 and 74 and Chapter V of the Actread with the Companies (Acceptance of Deposits)
Rules, 2014. Hence, no amount on account of principal or intereston public deposits was
outstanding as on the date of the balance sheet.
14. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:
Pursuant to provision of the Section 186 of the Act, the details of
loans and investment have been disclosed in notes to the financial statements.
15. SUBSIDIARY / JOINT VENTURES / ASSOCIATE COMPANIES:
The Company has only one subsidiary as on March 31, 2024. There are no
associates or joint venture companies within the meaning of Section 2(6) of the Act. There
has been no material change in the nature of the business of the subsidiaries.
Pursuant to the provisions of Section 129 (3) of the Act, the statement
containing salient features of the financial statements and performance of subsidiary and
its contribution to the overall performance of the Company during the period is attached
with the audited financial statements in form AOC-1 forms part of this directors'
report (Annexure - 1). The audited financial statements of subsidiary has also been placed
on the website of the Company at www.lincolnpharma.com.
During the year under review, no companies became or ceased to be the
subsidiary, joint ventures or associate companies of the company.
16. INSURANCE:
The Company has taken adequate insurance to cover the risks to its
directors, senior key managerial personnel, employees, property (land and buildings),
plant, equipment and other assets.
17. RISK MANAGEMENT POLICY:
The Company has built a comprehensive risk management framework that
seeks to identify all kinds of anticipated risks associated with the business and to take
remedial actions to minimize any kind of adverse impact on the Company. The
Company understands that risk evaluation and risk mitigation is an
ongoing process within the organization and is fully committed to identify and mitigate
the risks in the business. The identification of risks by Internal Audit Department is
done at strategic, business and operational levels and the risk management process of the
Company focuses mainly on five elements, viz. (i) Risk Identification (ii) Risk Assessment
(iii) Risk Monitoring (iv) Risk Mitigation; (v) Risk Reporting.
The Company has a risk management policy consistent with the provisions
of the Act and the SEBI Listing Regulations. The Risk Management committee is responsible
for assisting the board in understanding existing risks and reviewing the mitigation and
elimination plans for those. The major risks identified by the businesses and functions
are systematically addressed through mitigating actions on a continuing basis. The audit
committee is also looking after the area of financial risks and controls. The said policy
and constitution of the committee is available on the website of Company and can be
accessed at company weblink:
https://www.lincolnpharma.com/Investor/Other%20Policies/5.%20Risk%20Management%20Policy.pdf?_t=1691127263
18. RELATED PARTY TRANSACTIONS:
All related party transactions are entered into only after receiving
prior approval from the Audit Committee. Omnibus approvals are obtained each year for
transactions which are repetitive in nature. A statement of all related party transactions
entered into is placed before the Audit Committee and Board of Directors for its review on
a quarterly basis, specifying the nature, value and terms of the transaction.
During the year under review, the Company has entered into transactions
with related parties as defined under Section 2(76) of the Act read with Companies
(Specification of Definitions Details) Rules, 2014, SEBI Listing Regulations and
applicable accounting standards, which were in the ordinary course of business and on
arms' length basis and in accordance with the policy on related party transactions of
the Company. During the year, there was no material transaction with any related parties
as per the related party transactions policy of the Company and/or any other related party
transaction entered into by the Company that requires disclosure in Form AOC-2, hence,
disclosure in Form AOC- 2 is not applicable to the Company.
The disclosures pertaining to related party transactions as per the
applicable Accounting Standards form part of the notes to the financial statements
provided in this Annual Report.
In terms of Regulation 23 (9) of the SEBI Listing Regulations, the
Company has submitted related party transaction within prescribed time limit with the
stock exchange(s) for the each half year. The policy on related party transactions is
placed on the Company's website at
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LODR/
6.%20Policv%20on%20Related%20Party%20Transactions.pdf
19. CORPORATE SOCIAL RESPONSIBILITY (CSR):
The Company has adopted a CSR Policy incompliance with the provisions
of the Act inter alia to give directions and assistance to the Board for leading the CSR
initiatives of the Company. The Committee formulates and reviews the Annual Action Plan
and also monitors the progress of the CSR activities. The Company has spent ' 193.19 Lakhs
towards the CSR projects for the Financial Year 2023-24. The Company believes in
undertaking business in a way that will lead to overall development of all stakeholders
and society. The projects have been continuously monitored by the Board on a quarterly
basis.
In accordance with Section 135 of the Act and Rule 8 of the Companies
(Corporate Social Responsibility Policy) Rules, 2014 the report on CSR activities along
with its annexure as forms part of this directors' report (Annexure - 2).
20. HUMAN RESOURCES MANAGEMENT:
Lincoln has consistently focused on providing its employees a work
environment that promotes diversity and inclusion, free of any discrimination. It has a
robust employee engagement policy that helps it develop and retain a highly motivated
team.
Your Company continued to build sustenance around various aspects of
employee work life as well as organic ways of enhancing its image as an employer of
choice.
21. VIGIL MECHANISM / WHISTLE BLOWER POLICY:
Pursuant to Rule 7 of the Companies (Meetings of Boardand its Powers)
Rules, 2014 read with Section 177(10) ofthe Companies Act, 2013 ("Act") and
Regulations 22 of the Listing Regulations your Company has adopted a Vigil Mechanism
Framework ("Framework"), policy for directors and employees to report genuine
concerns has been implemented. The policy safeguards whistleblowers' rights to report
concerns or grievances and provides direct access to the chairman of the audit committee.
The said policy is available on the website of the Company and can be
accessed at
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LQDR/
5.%20Details%20of%20establishment%20of%20Whistle%20Blower%20Policy.pdf.
22. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:
The Company is committed to provide a safe and secure working
environment for all employees and create ambience in which all employees can work together
without any apprehension of sexual harassment.
In accordance with the requirements of the sexual harassment of women
at workplace (prevention, prohibition & redressal) Act, 2013 ("POSH Act")
and Rules made thereunder, the Company has formulated and implemented a policy which
mandates no tolerance against any conduct amounting to sexual harassment of women at
workplace. During the year under review, the Company has not received any complaint under
the policy. Appropriate reporting mechanisms are in place for ensuring protection against
Sexual Harassment and the right to work with dignity.
23. PARTICULARS OF EMPLOYEES:
The information required under Section 197(12) of the Actread with Rule
5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,
as forms part of this directors' report (Annexure - 3). The information required
under Rule 5(2) and (3)of the Companies (Appointment and Remunerationof Managerial
Personnel) Rules, 2014, including amendment thereto, is provided in the Annexure forming
part of the Report. In terms of the second proviso to Section 136(1) of the Act, the
Report and Accounts are being sent to the shareholders excluding the aforesaid Annexure.
Any shareholder interested in obtaining the same may write to the Company Secretary at the
registered office of the Company.
24. AUDITORS AND AUDITORS' REPORT:
A. STATUTORY AUDITORS:
M/s. Samir M. Shah & Associates, Chartered Accountants (Firm
Registration No.: 122377W) have been appointed as the Statutory Auditors of the Company
for a term of five years until the conclusion of 33rd Annual General Meeting of
the Company. The Auditors fulfil the eligibility and qualification norms as prescribed
under the Act, the Chartered Accountants Act, 1949 and rules and regulations issued
thereunder. In addition, the auditors hold a valid certificate issued by the Peer Review
Board of the Institute of Chartered Accountants of India (ICAI), a prerequisite for
issuing quarterly Limited Review reports.
The Auditor's Report on the standalone and consolidated financial
statements of the Company for the year ended 31st March, 2024 forms part of
this Annual Report and there are no qualifications, reservations, adverse remarks or
disclaimer made by the statutory auditors in their report.
B. COST AUDITOR:
As per the requirements of the Section 148 of the Act read with the
Companies (Cost Records and Audit) Rules, 2014 as amended from time to time, your Company
is required to maintain cost records for few of its products and accordingly, such
accounts are made and records have been maintained by the Company.
The board of directors on the recommendation of the audit committee,
appointed M/s. Kiran J. Mehta & Co., Cost Accountants (Firm Registration Number
000025), as the cost auditors of the Company to audit the cost records for the financial
year ended on March 31, 2024 as per Section 148 of the Act. M/s. Kiran J. Mehta & Co.,
Cost Accountants have confirmed that their appointment is within the limits of Section 141
(3) (g) of the Act and have also certified that they are free from any disqualifications
specified under Section 141 (3) and proviso to Section 148 (3) read with Section 141 (4)
of the Act.
As per the provisions of the Act, the remuneration payable to the cost
auditor is required to be placed before the members in a general meeting for their
ratification. Accordingly, a resolution seeking members' ratification for the
remuneration payable to M/s. Kiran J. Mehta & Co., cost auditors forms part of the
notice convening the AGM.
Relevant cost audit report for the year 2022-23 was submitted to the
Central Government within stipulated time and was free from any qualification or adverse
remarks.
C. SECRETARIAL AUDITOR:
As required by Section 204 of the Act, read with the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board has
appointed M/s. Vishwas Sharma & Associates, Practicing Company Secretaries
(Certificate of Practice Number: 16942) to conduct Secretarial Audit for the Financial
Year 2023-24. The Report of the Secretarial Audit in Form MR - 3 for the financial year
ended on March 31, 2024, is annexed to this Report (Annexure - 4).
COMMENT OF BOARD ON SECRETARIALAUDITORS' OBSERVATIONS:
With respect to the observations of the Secretarial Auditors':
Non Compliance under Regulation 17 of SEBI (LODR) Regulations, 2015
arose without any malafide intention and on account of Company taking fraction into
nearest integer as against Stock Exchange taking nearest higher integer in respect
requirement of minimum Independent director on the board being 1/3rd of total
strength. The Company has further remitted the fine on 22.08.2023 to NSE and BSE Limited
and intimate to the both exchanges regarding payment confirmation. And from 26th
May, 2023 the composition of the Board is in compliance with Regulation 17(1) of SEBI
(Listing Obligations & Disclosure Requirement) Regulations, 2015.
On the basis of advisory issued by NSE, company has revised
shareholding pattern of the company from the quarter ended December 31, 2015 to September
30, 2023 on account of misinterpretation while disclosing the names of Mr. Ishwarlal
Ambalal Patel and Mrs. Manguben Ishwarlal Patel, a Person Acting in Concert under the
category of Promoter Group.
a) ANNUAL SECRETARIAL COMPLIANCE REPORT:
Pursuant to SEBI Circular CIR/CFD/CMD1/27/2019 dated February 08, 2019,
Company has undertaken an audit for the financial year ended March 31,2024 for all
applicable SEBI Regulations and circulars / guidelines issued thereunder. The annual
secretarial compliance report issued by M/S. Vishwas Sharma & Associates, Practicing
Company Secretaries have been submitted to the stock exchanges within prescribed time
limit.
25. REPORTING OF FRAUDS BY AUDITORS:
During the year under review, the statutory auditors, cost auditors and
secretarial auditor have not reported any instances of frauds committed in the Company by
its officers or employees to the audit committee under Section 143 (12) of the Act.
26. MAINTENANCE OF COST RECORDS SPECIFIED BY THE CENTRAL GOVERNMENT
UNDER SECTION 148 OF THE ACT:
Pursuant to Section 148 (1) of the Act, read with the Companies (Cost
Records and Audit) (Amendment) Rules, 2014, the cost audit records maintained by the
Company in respect of drug and pharmaceuticals products of the Company are required to be
audited by a cost accountant.
27. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE
INSOLVENCY AND BANKRUPTCY CODE, 2016:
During the financial year ended on March 31, 2024, there is no
application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016
(31 of 2016) against the Company.
28. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT
THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR
FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:
During the Year under the review, there was no One Time Settlement of
loan taken from Banks or any financial Institutions. Hence, the difference in valuation
does not arise.
29. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:
Pursuant to the Regulation 34 (2) (f) of the SEBI Listing Regulations,
the initiatives taken by the Company from an environmental, social and governance
perspective, are provided in the Business Responsibility and Sustainability Report which
is forms part of this directors' report (Annexure - 5).
30. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE
EARNINGS AND OUTGO:
The information pertaining to conservation of energy, technology
absorption, foreign exchange earnings and outgo as required under Section 134 (3) (m) of
the Act read with Rule 8 (3) of the Companies (Accounts) Rules, 2014 forms part of this
Report (Annexure - 6).
31. PROHIBITION OF INSIDER TRADING:
In terms of the provisions of the Securities and Exchange Board of
India (Prohibition of Insider Trading) Regulations, 2015, as amended ("SEBI PIT
Regulations"), the Company has adopted the revised "Code of Conduct to Regulate,
Monitor and Report Trading by Insiders" ("the Code"). The Code is
applicable to promoters, all directors, designated persons and connected persons and their
immediate relatives, who are expected to have access to unpublished price sensitive
information relating to the Company. The Company has also formulated a Code of
Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
(UPSI)' in compliance with the PIT Regulations. The aforesaid codes are available on
the website of the Company and can be accessed at
https: //www.lincolnpharma.com/Investor/Other%20Policies/6.%20Policy%20on%20Code
%20of%20Practices%20and%20Procedures%20for%20Fair%20Disclosure%20of%20Unpublished%2
0Price%20Sensitive%20Information.pdf?_t=1691566912
32. ANNUAL RETURN:
Pursuant to provision of Section 92 (3) read with Section 134 (3) (a)
of the Act, the annual return as on March 31, 2024 is available on the website of the
Company at
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LQDR/
23.%20MGT-7%20Annual%20Return/Final-MGT-7-of-Lincoln-Pharma-for-the-FY-2023-24.pdf?_t=1694515735
33. MANAGEMENT DISCUSSION & ANALYSIS REPORT:
A separate section on Management Discussion and Analysis Report
("MD&A") forms part of this report as required under Regulation 34 (2) of
SEBI Listing Regulations.
34. CORPORATE GOVERNANCE REPORT:
The Company has a rich legacy of ethical governance practices and
committed to implement sound corporate governance practices with a view to bring about
transparency in its operations and maximize shareholder's value. A separate section
on corporate governance along with a certificate from the practicing company secretary
regarding compliance with the conditions of corporate governance as stipulated under
Schedule V of the SEBI Listing Regulations as forms part of this directors' report
(Annexure -7).
35. AUDIT COMMITTEE:
The details pertaining to the composition of the audit committee are
given in the report on corporate governance forming part of this Report. Further, all the
recommendations made by the audit committee were accepted by the Board.
36. SIGNIFICANT OR MATERIAL ORDER PASSED BY THE REGULATORS OR COURTS:
There are no significant and material orders passed during the year by
the regulators or courts or tribunals impacting the going concern status and operations of
the Company in future.
37. CAUTIONARY STATEMENT:
The annual report including those which relate to the directors'
report, management discussion and analysis report may contain certain statements on the
Company's intent expectations or forecasts that appear to be forward-looking within
the meaning of applicable securities laws and regulations while actual outcomes may differ
materially from what is expressed herein. The Company bears no obligations to update any
such forward looking statement. Some of the factors
that could affect the Company's performance could be the demand
and supply for Company's product and services, changes in government regulations, tax
laws, forex volatility etc.
38. ACKNOWLEDGEMENTS:
The Board of Directors acknowledges and places on record their sincere
appreciation of all stakeholders, customers, vendors, banks, Central and State Governments
and allother business partners, for their continued co-operationand for the excellent
support received from them.
The Board also wishes to place on record its appreciation to the
esteemed investors for showing their confidenceand faith in the management of the Company.
Your Directors recognize and appreciate the efforts and hard work of
all the employees of the Company and their continued contribution to promote its
development.
ANNEXURE - 1 TO THE DIRECTORS' REPORT
FORM AOC-1
(Pursuant to first proviso to sub-section (3) of section 129 read with
rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statements of
subsidiaries / associate companies / joint ventures Part "A": Subsidiaries
(as per section 2 (87) of the Act)
(' in Lakhs)
Particulars |
Details |
Name of the
Subsidiaries |
Zullinc
Healthcare LLP |
(Wholly-Owned
Subsidiary) |
The date
since when subsidiary was acquired. |
October 16,
2008 |
Reporting
period for the subsidiary concerned, if different from the holding company's
reporting period |
April 1,
2023 to March 31, 2024 |
Reporting
currency and Exchange rate as on the last date of the relevant Financial Year in the case
of foreign subsidiaries |
N.A. |
Share
Capital / Partners Contribution |
5.00 |
Reserves
and Surplus |
121.81 |
Total Assets |
140.86 |
Total
Liabilities |
14.05 |
Investments |
NIL |
Turnover |
NIL |
Profit
Before Taxation |
(0.54) |
Provision
for Taxation |
NIL |
Profit After
Taxation |
(0.54) |
Proposed
Dividend |
NIL |
% of
shareholding |
100% |
Notes:
1. There is no subsidiary which is yet to commence its operation.
2. The amounts given in the table above are from the annual accounts
made for the respective financial year end for each of the company.
Part "B": Associates / Joint Ventures (as per Section 2(6) of
the Act) - None
REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES
1. Brief outline on CSR Policy of the Company.
Company focus on areas like providing education, imparting skills,
promoting entrepreneurship and employment. It seeks to help people and communities bridge
the opportunity gap. The Company also supports health, wellness, water, sanitation and
hygiene needs of communities, especially those that are marginalized. By applying its
resources towards communities that need it the most, company ensures equitable access. The
Company's CSR strategy incorporates an inclusive approach into the design of every
program. Company aims to create innovative solutions to societal challenges applying its
contextual knowledge; execute and scale programs using its technology capabilities; engage
its large employee base to volunteer their time, skills. The projects undertaken are
within the broad framework of schedule VII of the Act. Details of the CSR policy and
projects or programs undertaken by the Company are available on the website of the Company
at www.lincolnpharma.com.
2. Composition of CSR Committee:
Sr. No. Name
of Director |
Designation
/ Nature of Directorship |
Number of
meetings of CSR Committee held during the year |
Number of
meetings of CSR Committee attended during the year |
1. Mr.
Mahendra G. Patel |
Member,
Executive Director |
3 |
3 |
2. Mr.
Munjal M. Patel |
Member,
Executive Director |
3 |
3 |
3. Ms. Meha
Patel* |
Member,
Non-Executive Independent Director |
3 |
3 |
4. Mr.
Pirabhai Ramjibhai Suthar** |
Member,
Non-Executive Independent Director |
- |
- |
*Ms. Meha Patel has resigned from the position of the Independent
Director of the Company with effect from the 16th February, 2024.
** Mr. Pirabhai Ramjibhai Suthar has been appointed as a Member of the
committee w.e.f February 16, 2024 on account of resignation of Ms. Meha Patel.
***The CSR Committee was reconstituted by inducting Ms.Seema Mehta as a
member on April 01, 2024, on account of Cessation of Mr. Pirabhai Suthar from Directorship
of the Company.
3. Provide the web-link where Composition of CSR committee, CSR Policy
and CSR projects approved by the board are disclosed on the website of the company:
https://www.lincolnpharma.com/Investor/Disclosures%20under%20Requlation%2046%20of%20the%20LQDR/
3.%20Composition%20of%20Various%20Committees%20of%20Board%20of%20Directors.pdf.pdf?_t=1712902451
.
4. Provide the executive summary along with web-link(s) of Impact
assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8, if
applicable: Not applicable
5. a) Average net profit of the Company as per Section 135 (5): '
9142.17 Lakhs
b) Two percent of average net profit as per section 135(5) : ' 182.84
Lakhs
c) Surplus arising out of the CSR projects or programmes or activities
of the previous financial years: ' 1.91 Lakhs
d) Amount required to be set off for the financial year, if any: ' 191
Lakhs
e) Total obligation for the financial year [(b)+(c)-(d)] : ' 18093
Lakhs
6. a) Amount spent on CSR Projects (both Ongoing Project and other than
Ongoing Project). Details of CSR amount spent against ongoing projects for the financial
year:
Sr.
No. |
Name
of the Project |
Item
from the list of activities in Schedule VII to the Act |
Local
area (Yes/No) |
Location
of the project |
Project
duration |
Amount
allocated for the project (' in Lakhs) |
Amount
spent in the current financial Year (? in Lakhs) |
Amount
transferred to Unspent CSR Account for the project as per Section 135(6)
(? in Lakhs) |
Mode
of
Implementation - Direct (Yes/No) |
Mode of Implementation - Through Implementing Agency |
State |
District |
Name |
CSR
Registration
number |
Nil |
Details of CSR amount spent against other than ongoing projects for the
financial year:
Name of the Project |
Item from the list of activities in Schedule VII to the Act |
Local
area (Yes/No) |
Location
of the project |
Amount
allocated for the project (? in Lakhs) |
Amount
spent for the Project (? in Lakhs) |
Mode
of Implementation - Direct (Yes/No) |
Mode
of
Implementation - Through Implementing Agency |
State |
District |
Name |
CSR
Registration
number |
Providing support to the differently abled |
Clause (ii) Promoting education to differently abled
people |
Yes |
GJ |
AHM |
12.52 |
12.52 |
No |
Blind
People's Association |
CSR00000936 |
Contribution |
Clause (ii) |
Yes |
GJ |
AHM |
4.00 |
4.00 |
No |
Dr.
Jit Mehta |
CSR00010884 |
towards education Promoting |
|
|
|
|
|
|
|
Balshala
Trust |
|
activities |
Education |
|
|
|
|
|
|
|
|
Contribution |
Clause (i) |
Yes |
GJ |
AHM |
21.00 |
21.00 |
No |
Shardaben |
CSR00007105 |
towards
education |
Promoting |
|
|
|
|
|
|
Gulabdas
Patel |
|
activities |
Education |
|
|
|
|
|
|
Public
Charity |
|
|
|
|
|
|
|
|
|
Trust |
|
Contribution |
Clause (i) |
Yes |
GJ |
Mehsana |
16.70 |
16.70 |
No |
Shri
Sarswati |
CSR00008338 |
towards education |
Promoting |
|
|
|
|
|
|
Kanya
Kelavani |
|
activities |
Education |
|
|
|
|
|
|
Mandal |
|
Contribution |
Clause (i) |
Yes |
GJ |
AHM |
11.00 |
11.00 |
No |
Shri
Daran Juth |
CSR00045270 |
towards education Promoting |
|
|
|
|
|
|
Kelvani
Uttejak |
|
activities |
Education |
|
|
|
|
|
|
Mandal |
|
Contribution |
Clause (i) |
No |
DL |
DL |
0.36 |
0.36 |
No |
Smile
Foundation |
CSR00001634 |
towards education Promoting |
|
|
|
|
|
|
|
|
activities |
Education |
|
|
|
|
|
|
|
|
Contribution |
Clause (i) |
Yes |
GJ |
AHM |
40.83 |
40.83 |
No |
Sri
Sathya Sai |
CSR00007410 |
towards healthcare Promoting |
|
|
|
|
|
|
Heart
Hospital |
|
activities |
healthcare |
|
|
|
|
|
|
|
|
Contribution |
Clause (i) & (ii) |
Yes |
GJ |
AHM |
3.55 |
3.55 |
No |
Tathastu |
CSR00005063 |
towards hunger, |
Eradicating hunger, |
|
|
|
|
|
|
Foundation |
|
education & |
poverty and |
|
|
|
|
|
|
|
|
healthcare |
malnutrition and |
|
|
|
|
|
|
|
|
activities |
promoting education |
|
|
|
|
|
|
|
|
Name
of the Project |
Item
from the list of activities in Schedule VII to the Act |
Local
area (Yes/No) |
Location
of the project |
Amount
allocated for the project (? in Lakhs) |
Amount
spent for the Project (? in Lakhs) |
Mode
of Implementation - Direct (Yes/No) |
Mode
of
Implementation - Through Implementing Agency |
State |
District |
Name |
CSR
Registration
number |
Contribution
towards hunger, education & healthcare activities |
Clause
(i) & (ii) Eradicating hunger, poverty and malnutrition and promoting education |
Yes |
GJ |
AHM |
15.90 |
15.90 |
No |
Vicharta
Samuday
Samarthan
Manch |
CSR00001129 |
Contribution
towards
healthcare
activities |
Clause
(i) Promoting healthcare |
Yes |
GJ |
AHM |
12.63 |
12.63 |
No |
Setu
Charitable
Trust |
CSR00029527 |
Contribution
towards
education
activities |
Clause
(ii) Promoting Education |
Yes |
GJ |
AHM |
0.40 |
0.40 |
No |
Saptak
School of Music |
CSR00010400 |
Contribution
towards
education
activities |
Clause
(ii) Promoting Education |
Yes |
GJ |
AHM |
10.00 |
10.00 |
No |
Sardardham |
CSR00003148 |
Providing
facilities for senior citizens |
Clause
(iii) Providing fa cilities for senior citizens |
Yes |
GJ |
AHM |
3.50 |
3.50 |
No |
Manav
Seva Samaj Kalyan Trust Bank |
CSR00015827 |
Contribution
towards hunger, education & healthcare activities |
Clause
(i) & (ii) Eradicating hunger, poverty and malnutrition and promoting education |
No |
DL |
DL |
2.00 |
2.00 |
No |
Ma h a r
a ja Agrasen Jan Kalyan Samiti Manch |
CSR00027160 |
Contribution
towards
healthcare
activities |
Clause
(i) Promoting healthcare |
Yes |
GJ |
Mehsana |
2.00 |
2.00 |
No |
Kadi
Taluka Public
Charitable Trust |
CSR00015465 |
Contribution
towards
education
activities |
Clause
(ii) Promoting Education |
Yes |
GJ |
Mehsana |
32.29 |
32.29 |
Yes |
Irana
Primary School |
N.A |
Contribution
towards
healthcare
activities |
Clause
(i) Promoting healthcare |
No |
GJ |
AHM |
2.00 |
2.00 |
No |
CIMS
Foundation |
CSR00003995 |
Providing
support to the differently abled |
Clause
(ii) Promoting education to differently abled people |
Yes |
GJ |
BH |
2.51 |
2.51 |
No |
Ankur
School For Mentally Retarded Children |
CSR00001417 |
* GJ - Gujarat, AHM - Ahmedabad TN-Tamilnadu, COI-Coimbtor *DL-Delhi
*BH- Bhavnagar b) Amount spent in administrative overheads: Nil
c) Amount spent on Impact Assessment, if applicable: Nil
d) Total amount spent for the Financial Year (a+b+c): ' 193.19 Lakhs
e) CSR amount spent or unspent for the financial year:
Total
Amount |
Amount Unspent (in ') |
Spent for
the Financial Year. |
Total Amount transferred to Unspent CSR Account as per section 135(6) |
Amount transferred to any fund specified under Schedule VII as per second
proviso to section 135(5) |
(in ') |
Amount |
Date of
Transfer |
Name of the
Fund |
Amount |
Date of
Transfer |
' 193.19
Lakhs |
|
Not Applicable |
f) Excess amount for set off, if any:
Sr. No.
Particular |
' in Lakhs |
i. Two
percent of average net profit of the company as per section 135(5) |
182.84 |
ii. Total
amount spent for the financial year |
193.19 |
iii. Excess
amount spent for the financial year [(ii)-(i)] |
12.26 |
iv. Surplus
arising out of the CSR projects or programmes or activities of the previous financial
years, if any |
NIL |
v. Amount
available for set off in succeeding financial years [(iii)-(iv)] |
12.26 |
7 a) Details of unspent CSR amount for the preceding three financial
years:
Sr. No.
Preceding Financial Year |
Amount
transferred to Unspent CSR Account under subsection (6) of section 135 (6) |
Balance
Amount in Unspent CSR Account under subsection(6) |
Amount
spent in the Financial Year (? in |
Amount transferred
to a fund as specified under
Schedule VII as per second
proviso to sub section (5)
of section 135, if any |
Amount
remaining to be spent in succeeding financial |
Deficiency,
if any |
|
(' in
Lakhs) |
of
section 135 (in ') |
Lakhs) |
Amount (?
in Lakhs) |
Date of
transfer |
years ('
in Lakhs) |
|
FY-1 |
|
|
|
|
|
|
FY-2 |
|
Not Applicable |
|
|
FY-3 |
|
|
|
|
|
|
b) Details of CSR amount spent in the financial year for ongoing
projects of the preceding financial year(s):
Sr. No.
Project ID |
Name of
Project |
Financial
Year in which the project was commenced |
Project
duration |
Total
amount allocated for the project (' in Lakhs) |
Amount
spent on the project in the reporting Financial Year (' in Lakhs) |
Cumulative
amount spent at the end of reporting Financial Year (' in Lakhs) |
Status
of the project - Completed / Ongoing |
Not
Applicable |
8. Whether any capital assets have been created or acquired through
Corporate Social Responsibility amount spent in the Financial Year:
Yes 3 No
If yes, enter the number of Capital assets created/ acquired N.A
Furnish the details relating to such asset(s) so created or acquired
through Corporate Social Responsibility amount spent in the Financial Year:
Sr. Short
particulars of the property or asset(s) |
Pincode
of the |
Date
of |
Amount
of CSR |
Details of entity/ Authority/ beneficiary of the registered owner |
No. [including
complete address and location of the property] |
property
or asset(s) |
creation |
amount
spent |
CSR
Registration Number, if applicable |
Name |
Registered
address |
(1) (2) |
(3) |
(4) |
(5) |
(6) |
(7) |
(8) |
NA |
9. Specify the reason(s), if the company has failed to spend two per
cent of the average net profit as per section 135(5)
Not Applicable
ANNEXURE - 3 TO THE DIRECTORS' REPORT
STATEMENT OF PARTICULARS AS PER RULE 5 OF COMPANIES (APPOINTMENT AND
REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014.
The remuneration and perquisites provided to the employees and
management are at par with the industry levels. The remunerations paid to the directors
and key managerial personnel are reviewed and recommended by the nomination and
remuneration committee.
1) The Ratio of the remuneration of each director to the median
remuneration of the employees of the company for the Financial Year Ended March 31, 2024; ('
in Lakhs)
SN Name
of Directors |
Remuneration
(Per Annum) |
Ratio |
1. Mr.
Mahendra G. Patel |
49.25 |
8:1 |
2. Mr.
Hashmukh I. Patel |
38.05 |
6:1 |
3. Mr.
Ashish R. Patel |
66.44 |
11:1 |
4. Mr.
Munjal M. Patel |
66.47 |
11:1 |
2) The percentage increase in remuneration of each Director,
Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in
the Financial Year Ended March 31, 2024;
SN Name
of Directors / KMP |
Designation |
%
Increase |
1. Mr.
Mahendra G. Patel |
Managing
Director |
52.84 |
2. Mr.
Hashmukh I. Patel |
Whole-Time
Director |
14.44 |
3. Mr.
Ashish R. Patel |
Whole-Time
Director |
24.54 |
4. Mr.
Munjal M. Patel |
Whole-Time
Director |
93.12 |
5. Mr.
Anand A. Patel |
Whole-Time
Director (Resigned w.e.f 25.05.2023) |
NA |
6. Mr.
Darshit A. Shah |
Chief
Financial Officer |
12.22 |
7. Ms.
Trusha Shah* |
Company
Secretary |
NA |
The other directors are non-executive directors and they are not
receiving remuneration and sitting fees during the financial year ended March 31, 2024.
*Trusha Shah designated as Company Secretary and Compliance Officer
w.e.f. 10 th November, 2022. Hence remuneration paid during 2022-23 was for
part of the year and not comparable with 2023-24.
3) The percentage increase in the median remuneration of employees in
the financial year ended March 31, 2024: 12.27%
4) The number of permanent employees on the rolls of company; There
are 1,687 permanent employees on the rolls of the Company.
5) Average percentile increase already made in the salaries of
employees other than the managerial personnel in the last financial year and its
comparison with the percentile increase in the managerial remuneration and justification
thereof and point out if there are any exceptional circumstances for increase in the
managerial remuneration;
The average increase in salaries of employees other than managerial
personnel in 2023-2024 was about 12.22%. Percentage increase in the managerial
remuneration for the year was 43.70%. The increase in managerial remuneration is as per
the resolution approved by shareholders in the general meeting and inconsistent with the
overall performance of the company. Annual increment in the salary is based on the
different grades, industry pattern, qualification, expertise and experience of individual
employee. As such the annual increment in remuneration is as per the terms of appointment
and is in conformity with the remuneration policy of the Company.
6) the key parameters for any variable component of remuneration
availed by the directors;
No such variable component is included in the remuneration paid to
directors.
7) Affirmation that the remuneration is as per the remuneration policy
of the Company:
The remuneration paid to key managerial personnel is as per the
remuneration policy of the Company.
Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31st March, 2024
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of
the Companies (Appointment and Remuneration Personnel) Rules, 2014]
To,
The Members,
Lincoln Pharmaceuticals Limited,
(CIN: - L24230GJ1995PLC024288),
"LINCOLN HOUSE", Behind Satyam Complex,
Science City Road, Sola, Ahmedabad - 380060
We have conducted the secretarial audit of the compliance of applicable
statutory provisions and the adherence to good corporate practices by the applicable
statutory provisions and the adherence to good corporate practices by Lincoln
Pharmaceuticals Limited (CIN: - L24230GJ1995PLC024288) (hereinafter called "the
Company"). Secretarial Audit was conducted in amanner that provided me a reasonable
basis for evaluating the corporate conducts/statutory compliances and expressing my
opinion thereon.
Based on our verification of the Company's books, papers, minute
books, forms and returns filed and other records maintained by the Company and also the
information provided by the Company, its officers, agents and authorized representatives
during the conduct of secretarial audit, I hereby report that in my opinion, the Company
has, during the audit period covering the financial year ended on March 31,2024
(Audit Period')complied with the statutory provisions listed hereunder and also
that the Company has proper Board-processes and compliance-mechanism in place to the
extent, in the manner and subject to the reporting made hereinafter:
We have examined the books, papers, minute books, forms and returns
filed and other records maintained by the Company for the financial year ended on March
31, 2024 according to the provisions of:
i. The Companies Act, 2013 (the Act) and the rules made there under.
ii. The Securities Contracts (Regulation) Act, 1956 (SCRA')
and the rules made thereunder;
iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed
thereunder;
iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations
made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and
External Commercial Borrowing.
v. The following Regulations and Guidelines prescribed under the
Securities and Exchange Board of India Act, 1992 (SEBI Act'):-
(a) The Securities and Exchange Board of India (Substantial Acquisition
of Shares and Takeovers) Regulations, 2011 ;
(b) The Securities and Exchange Board of India (Prohibition of Insider
Trading) Regulations, 2015 ;.
(c) The Securities and Exchange Board of India (Issue of Capital and
Disclosure Requirements) Regulations, 2018;.
(d) The Securities and Exchange Board of India (Share Based Employee
Benefits) Regulations, 2021 (Not Applicable to
the company during the audit period);
(e) The Securities and Exchange Board of India (Issue and Listing of
Non-convertible Securities) Regulations, 2021 (Not Applicable to the company during the
audit period);
(f) The Securities and Exchange Board of India (Registrars to an Issue
and Share Transfer Agents) Regulations, 1993 regarding companies Act and dealing with
client;
(g) The Securities and Exchange Board of India (Delisting of Equity
Shares) Regulations, 2021 (Not Applicable to the company during the audit period);
(h) The Securities and Exchange Board of India (Buyback of Securities)
Regulations, 2018 (Not Applicable to the company during the audit period);
I have relied on the representations made by the Company and its
officers for systems and mechanism formed by the Company for compliances system prevailing
in the Company and on examination of the relevant documents and records in pursuance
thereof, on test-check basis, the Company has complied with the provisions of The Drugs
and Cosmetics Act, 1940 and The Factories Act, 1948 and rules made thereunder, as is
specifically applicable to the Company.
I have also examined compliance with the applicable Clauses of the
following:
i. Secretarial Standards issued by The Institute of Company Secretaries
of India;
ii. Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015 During the period under review the Company has
complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. subject
to following observations.
1) The Company has failed to complied /delayed complied with Regulation
17(1) of SEBI (LODR)Regulations 2015 as the composition of Board was not incompliance with
the Regulation till 25.05.2023. Both the Exchanges (i.e NSE &BSE) has imposed fine of
' 3,24,500/- respectively on the Company after June 30, 2023. However, The Company has
paid the requisite fine.
2) The Company has disclosed the names of Mr. Ishwarlal Ambalal Patel and
Mrs. Manguben Ishwarlal Patel, a Person Acting in Concert under the category of Promoter
Group on account of misinterpretation while filing the Shareholding Pattern from the
quarter ended December 31, 2015 to September 30,2023.NationalStock Exchange (NSE) has
advised the company to revise the Shareholding Pattern for the aforesaid period and
company has revised the same which was taken on record by the exchange.
I further report that:
The Board of Directors of the Company is duly constituted with proper
balance of Executive Directors, Non-Executive Directors and Independent Directors
including one Woman Independent Director. The changes in the composition of the Board of
Directors, if any, that took place during the period underreview were carried out in
compliance with the provisions of the Act.
Adequate notice is given to all the directors to schedule the Board
Meetings, agenda and detailed notes on agenda were sent at least seven days in advance,
and a system exists for seeking and obtaining further information and clarifications on
the agenda items before the meeting and for meaningful participation at the meeting.
Board takes decision by majority of directors while the dissenting
directors' views are captured and recorded as part of the minutes.
I further report that:
There are adequate systems and processes in the company commensurate
with the size and operations of the company to monitor and ensure compliance with
applicable Laws, Rules, Regulations and guidelines.
I further report that, during the period, the Company has recommended
the dividend of Rs. 1.80/- (i.e. 18% per share) per equity share of face value of Rs. 10/-
for the year ended on March 31, 2024.
I further report that during the audit period, the Company has no other
instances of:
i. Public/Rights of Shares/Preferential Issue of
Shares/debentures/sweat equity;
ii. Redemption/buy-back of securities;
iii. Major decisions taken by the members in pursuance to section 180
of the Companies Act, 2013;
iv. Merger/ amalgamation etc.;
v. Foreign technical collaborations.
Annexure to Secretarial Audit Report
To,
The Members,
LINCOLN PHARMACEUTICALS LIMITED,
"LINCOLN HOUSE", Behind Satyam Complex,
Science City Road, Sola, Ahmedabad - 380060
My report of even date is to be read along with this letter.
1. Maintenance of secretarial records is the responsibility of the
management of the Company. My responsibility is to express an opinion on these secretarial
records based on my audit.
2. I have followed the audit practices and processes as were
appropriate to obtain reasonable assurance about the correctness of the contents of the
secretarial records. The verification was done on test basis to ensure that correct facts
are reflected in secretarial records. I believe that the processes and practices, I
followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial
records and Books of Accounts of the Company.
4. Wherever required, I have obtained the Management representations
about the compliance of Laws, Rules and Regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable
Laws, Rules, Regulations, Standards is the responsibility of management. My examination
was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the
future viability of the Company nor of the efficacy or effectiveness with which the
management has conducted the affairs of the Company.